Charles River Laboratories International, Inc. $CRL Shares Purchased by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT raised its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 9.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,522 shares of the medical research company’s stock after purchasing an additional 969 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Charles River Laboratories International were worth $1,748,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CRL. Exchange Traded Concepts LLC grew its holdings in shares of Charles River Laboratories International by 1.3% during the second quarter. Exchange Traded Concepts LLC now owns 5,742 shares of the medical research company’s stock worth $871,000 after buying an additional 76 shares during the last quarter. Brooklyn Investment Group lifted its position in Charles River Laboratories International by 93.5% during the 1st quarter. Brooklyn Investment Group now owns 178 shares of the medical research company’s stock worth $27,000 after acquiring an additional 86 shares during the period. DekaBank Deutsche Girozentrale lifted its position in Charles River Laboratories International by 1.2% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,142 shares of the medical research company’s stock worth $1,072,000 after acquiring an additional 86 shares during the period. WESCAP Management Group Inc. grew its stake in shares of Charles River Laboratories International by 3.8% in the 2nd quarter. WESCAP Management Group Inc. now owns 2,443 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 89 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its holdings in shares of Charles River Laboratories International by 2.7% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 3,916 shares of the medical research company’s stock valued at $589,000 after purchasing an additional 102 shares during the period. 98.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on CRL shares. Wall Street Zen downgraded Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday. Evercore ISI raised their target price on shares of Charles River Laboratories International from $190.00 to $200.00 and gave the stock an “outperform” rating in a research note on Friday, October 3rd. William Blair raised shares of Charles River Laboratories International from a “market perform” rating to an “outperform” rating in a report on Monday, October 6th. Robert W. Baird raised shares of Charles River Laboratories International from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $178.00 to $199.00 in a report on Thursday. Finally, Baird R W upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, six have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $186.93.

Charles River Laboratories International Stock Down 1.7%

CRL stock opened at $167.99 on Monday. The company has a market cap of $8.27 billion, a P/E ratio of -126.31, a P/E/G ratio of 4.83 and a beta of 1.53. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $222.10. The company’s 50-day moving average price is $168.00 and its 200 day moving average price is $155.67. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $990.43 million. During the same period last year, the company posted $2.59 earnings per share. The firm’s quarterly revenue was down .5% compared to the same quarter last year. On average, research analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the company’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president owned 24,116 shares of the company’s stock, valued at approximately $3,800,681.60. This represents a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.30% of the stock is owned by insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).